K2 Principal Fund L.P. Takes Position in Catalent, Inc. (NYSE:CTLT)

K2 Principal Fund L.P. acquired a new stake in Catalent, Inc. (NYSE:CTLT) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 33,048 shares of the company’s stock, valued at approximately $1,858,000.

A number of other large investors have also recently added to or reduced their stakes in CTLT. Marshall Wace LLP lifted its position in Catalent by 5.1% in the second quarter. Marshall Wace LLP now owns 1,792,951 shares of the company’s stock valued at $100,818,000 after buying an additional 86,533 shares during the last quarter. Slotnik Capital LLC lifted its holdings in shares of Catalent by 8.9% in the 2nd quarter. Slotnik Capital LLC now owns 195,500 shares of the company’s stock worth $10,993,000 after acquiring an additional 16,000 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Catalent by 222.0% during the 2nd quarter. Bank of Montreal Can now owns 644,123 shares of the company’s stock worth $36,219,000 after purchasing an additional 444,084 shares during the period. Public Sector Pension Investment Board increased its holdings in Catalent by 65.7% in the 2nd quarter. Public Sector Pension Investment Board now owns 6,810 shares of the company’s stock valued at $383,000 after purchasing an additional 2,701 shares during the last quarter. Finally, HighVista Strategies LLC purchased a new stake in Catalent in the second quarter valued at approximately $4,251,000.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, July 11th. Barclays boosted their price target on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, June 28th. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, StockNews.com assumed coverage on shares of Catalent in a research note on Wednesday, September 18th. They set a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $58.08.

Insider Transactions at Catalent

In related news, insider Ricky Hopson sold 662 shares of the stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the transaction, the insider now directly owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Catalent news, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now owns 39,635 shares of the company’s stock, valued at $2,360,264.25. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Ricky Hopson sold 662 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the completion of the sale, the insider now owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,409 shares of company stock worth $782,923. 0.31% of the stock is currently owned by insiders.

Catalent Stock Down 0.5 %

Shares of Catalent stock opened at $59.73 on Tuesday. The company has a quick ratio of 1.77, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. Catalent, Inc. has a 52-week low of $31.80 and a 52-week high of $61.20. The company has a market capitalization of $10.81 billion, a P/E ratio of -9.79, a P/E/G ratio of 1.88 and a beta of 1.15. The company has a 50 day moving average of $59.52 and a 200 day moving average of $57.24.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.13. The business had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. As a group, research analysts forecast that Catalent, Inc. will post 1.06 EPS for the current fiscal year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.